---
title: Use of Continuous Glucose Monitors in Publicly-Insured Youth With Type 2 Diabetes - A Pilot and Feasibility Study
nct_id: NCT05074667
overall_status: COMPLETED
phase: NA
sponsor: Stanford University
study_type: INTERVENTIONAL
primary_condition: Type 2 Diabetes
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05074667.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05074667"
ct_last_update_post_date: 2024-07-31
last_seen_at: "2026-05-12T07:18:28.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Use of Continuous Glucose Monitors in Publicly-Insured Youth With Type 2 Diabetes - A Pilot and Feasibility Study

**NCT ID:** [NCT05074667](https://clinicaltrials.gov/study/NCT05074667)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Stanford University
- **Conditions:** Type 2 Diabetes
- **Start Date:** 2021-12-01
- **Completion Date:** 2023-06-25
- **CT.gov Last Update:** 2024-07-31

## Brief Summary

The purpose of this pilot feasibility study is to provide continued CGM access to youth with type 2 diabetes and collect descriptive data about feasibility of use of CGM in youth with type 2 diabetes ages 4 years and older. From this study the investigators hope to learn if CGM use in youth with type 2 diabetes can be tolerated and sustained with good adherence and to describe blood glucose patterns in youth with type 2 diabetes. The primary aim will be to evaluate the feasibility of CGM start and continuation in youth with T2D and describe glucose metrics and patient reported outcomes (PROs). The investigators will pilot and refine a program to test the hypothesis that CGM start and continuation in youth with T2D is feasible and then evaluate glucose metrics and PROs.

## Eligibility

- **Minimum age:** 4 Years
- **Maximum age:** 19 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* public insurance
* between ages 4-19.99 years inclusive
* diagnosis of T2D (diabetes autoantibody negative) followed in the Pediatric Endocrinology clinic at Stanford Children's Health
* HbA1C greater than 6.5% at enrollment
* interested in starting on a continuous glucose monitor
* have access to a mobile device that is compatible with CGM applications or willing to use CGM receiver provided

Exclusion Criteria:

* non-T2D diagnosis
* HgA1C \< 6.5%
* are not willing to wear CGM
* have private health insurance.
```

## Arms

- **Continuous Glucose Monitor** (OTHER) — All participants will be included in this arm

## Interventions

- **Continuous Glucose Monitor** (DEVICE) — Participants will be provided a continuous glucose monitor for use in self-glucose monitoring as per standard clinical care
- **Patient Reported Outcome Questionnaires** (OTHER) — Participants and their parents will be asked to complete patient reported outcome questionnaires at 3 study time points.

## Primary Outcomes

- **Number of Participants With at Least 75% Wear Time Over 14 Days as a Measure of Sustained CGM Use** _(time frame: months 2,3,6,9 and 12 (assessed over the 14 days prior to each clinic visit))_

## Secondary Outcomes

- **Mean HbA1C** _(time frame: baseline and months 2,3,6,9 and 12)_
- **Time With Glucose Values in Target Range of 70-180 mg/dL** _(time frame: months 2,3,6,9 and 12 (assessed over the 14 days prior to each clinic visit))_
- **PROMIS Global Health Overall Scale Score** _(time frame: baseline, months 3 and 12)_
- **PedsQL 3.2 Overall Scale Score - Participant Rated** _(time frame: baseline and months 3 and 12)_
- **PedsQL 3.2 Scale Score - Parent Rated** _(time frame: baseline and months 3 and 12)_
- **Diabetes Technology Attitudes (DTA) - Participant Rated** _(time frame: 1 year (assessed at baseline, 3 months and 12 months))_
- **Diabetes Technology Attitudes (DTA) - Parent Rated** _(time frame: 1 year (assessed at baseline, 3 months and 12 months))_
- **Problem Areas in Diabetes-Teen Version (PAID-T) Overall Scale Score - Participant Rated** _(time frame: baseline, months 3 and 12)_
- **Problem Areas in Diabetes (P-PAID) Overall Scale Score - Parent Rated** _(time frame: baseline, months 3 and 12)_

## Locations (1)

- Stanford Children's Health, Palo Alto, California, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.stanford children's health|palo alto|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05074667.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05074667*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*